AU2019210414B2 - Pyridone derivative, composition thereof and application thereof as anti-influenza drug - Google Patents

Pyridone derivative, composition thereof and application thereof as anti-influenza drug Download PDF

Info

Publication number
AU2019210414B2
AU2019210414B2 AU2019210414A AU2019210414A AU2019210414B2 AU 2019210414 B2 AU2019210414 B2 AU 2019210414B2 AU 2019210414 A AU2019210414 A AU 2019210414A AU 2019210414 A AU2019210414 A AU 2019210414A AU 2019210414 B2 AU2019210414 B2 AU 2019210414B2
Authority
AU
Australia
Prior art keywords
carbonyl
ring
hydrocarbyl
compound
hydrocarbylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019210414A
Other languages
English (en)
Other versions
AU2019210414A1 (en
Inventor
Li Chen
Xiaowen LI
Qing SHAO
Xiaojian XUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Caishi Pharmaceutical Technology Co Ltd
Original Assignee
Jiangxi Caishi Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810044308.4A external-priority patent/CN110041327B/zh
Priority claimed from CN201811517425.4A external-priority patent/CN111303147B/zh
Application filed by Jiangxi Caishi Pharmaceutical Technology Co Ltd filed Critical Jiangxi Caishi Pharmaceutical Technology Co Ltd
Publication of AU2019210414A1 publication Critical patent/AU2019210414A1/en
Application granted granted Critical
Publication of AU2019210414B2 publication Critical patent/AU2019210414B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AU2019210414A 2018-01-17 2019-01-16 Pyridone derivative, composition thereof and application thereof as anti-influenza drug Active AU2019210414B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810044308.4A CN110041327B (zh) 2018-01-17 2018-01-17 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN201810044308.4 2018-01-17
CN201811517425.4 2018-12-12
CN201811517425.4A CN111303147B (zh) 2018-12-12 2018-12-12 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
PCT/CN2019/071902 WO2019141179A1 (zh) 2018-01-17 2019-01-16 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用

Publications (2)

Publication Number Publication Date
AU2019210414A1 AU2019210414A1 (en) 2020-09-03
AU2019210414B2 true AU2019210414B2 (en) 2021-04-01

Family

ID=67301986

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019210414A Active AU2019210414B2 (en) 2018-01-17 2019-01-16 Pyridone derivative, composition thereof and application thereof as anti-influenza drug

Country Status (11)

Country Link
US (1) US11247993B2 (https=)
EP (1) EP3753936B1 (https=)
JP (1) JP7352297B2 (https=)
KR (1) KR102477187B1 (https=)
CN (4) CN111848615B (https=)
AU (1) AU2019210414B2 (https=)
CA (1) CA3088926A1 (https=)
PH (1) PH12020551264A1 (https=)
SG (1) SG11202011447UA (https=)
WO (1) WO2019141179A1 (https=)
ZA (1) ZA202007143B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
JP6924839B2 (ja) 2017-10-06 2021-08-25 塩野義製薬株式会社 置換された多環性ピリドン誘導体の立体選択的な製造方法
KR20230031990A (ko) 2018-02-28 2023-03-07 노파르티스 아게 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물
WO2020205835A1 (en) * 2019-04-01 2020-10-08 Nikang Therapeutics, Inc. Fused polycyclic pyridone compounds as influenza virus replication inhibitors
CN111909174B (zh) 2019-05-08 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物的晶型及制备方法和应用
CN112574170A (zh) * 2019-09-29 2021-03-30 江西东邦药业有限公司 一种二苯并七元环衍生物及其制备方法和应用
CN118480041A (zh) * 2019-12-23 2024-08-13 石家庄迪斯凯威医药科技有限公司 取代的多环化合物及其药物组合物和用途
CN113045589B (zh) * 2019-12-27 2024-08-23 广东东阳光药业股份有限公司 流感病毒复制抑制剂及其用途
CN112898346B (zh) * 2020-01-23 2023-11-10 南京知和医药科技有限公司 水溶性多环化合物及其药物组合物和用途
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
CN111943879A (zh) * 2020-08-03 2020-11-17 南通大学 一种（3s，4r）3-氨基-4（甲氧基甲基）吡咯烷-1-甲酸叔丁酯及其合成方法
CN120289488A (zh) * 2020-08-11 2025-07-11 石家庄迪斯凯威医药科技有限公司 多环化合物及其药物组合物和用途
WO2022247759A1 (zh) * 2021-05-22 2022-12-01 江西彩石医药科技有限公司 吡啶酮衍生物的中间体及其制备方法
WO2024074080A1 (zh) * 2022-10-08 2024-04-11 石家庄迪斯凯威医药科技有限公司 一种抗流感病毒衍生物及其用途
CN117924325A (zh) * 2022-11-09 2024-04-26 石家庄迪斯凯威医药科技有限公司 一种抗流感病毒衍生物及其用途
CN116789556A (zh) * 2023-05-26 2023-09-22 康化（上海）新药研发有限公司 一种含环丙氧基乙胺的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6249434B1 (ja) * 2016-08-10 2017-12-20 塩野義製薬株式会社 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2444400T (lt) 2009-06-15 2018-06-11 Shionogi & Co., Ltd. Pakeistasis policiklinis karbamoilpiridono darinys
MX2013003139A (es) 2010-09-24 2013-06-18 Shionogi & Co Profarmaco de derivado de carbamoilpiridona policiclica substituida.
WO2015038655A1 (en) * 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
MX394421B (es) * 2015-04-28 2025-03-24 Shionogi & Co Derivados de piridona policiclica sustituida y profarmaco de los mismos
BR112017022550B1 (pt) * 2015-04-28 2021-02-23 Shionogi & Co., Ltd derivados policíclicos de piridona substituída
AU2016374416A1 (en) 2015-12-15 2018-06-14 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
JP6806413B2 (ja) * 2016-02-03 2021-01-06 塩野義製薬株式会社 多環性ピリドン誘導体およびそのプロドラッグ
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6249434B1 (ja) * 2016-08-10 2017-12-20 塩野義製薬株式会社 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物

Also Published As

Publication number Publication date
EP3753936A4 (en) 2022-03-23
EP3753936A1 (en) 2020-12-23
PH12020551264A1 (en) 2021-05-31
CN111848615B (zh) 2022-05-17
AU2019210414A1 (en) 2020-09-03
US11247993B2 (en) 2022-02-15
SG11202011447UA (en) 2020-12-30
CN110637016A (zh) 2019-12-31
ZA202007143B (en) 2022-04-28
KR20200118062A (ko) 2020-10-14
US20190367517A1 (en) 2019-12-05
CN111848615A (zh) 2020-10-30
CA3088926A1 (en) 2019-07-25
WO2019141179A1 (zh) 2019-07-25
JP2021511374A (ja) 2021-05-06
JP7352297B2 (ja) 2023-09-28
CN111848616B (zh) 2021-11-23
EP3753936B1 (en) 2026-04-08
CN111848616A (zh) 2020-10-30
CN111848614A (zh) 2020-10-30
CN111848614B (zh) 2021-11-23
CN110637016B (zh) 2020-08-18
KR102477187B1 (ko) 2022-12-12

Similar Documents

Publication Publication Date Title
AU2019210414B2 (en) Pyridone derivative, composition thereof and application thereof as anti-influenza drug
CA2930209C (en) Tetrahydroimidazopyridine derivatives as modulators of tnf activity
CA2930754C (en) Pyrazolopyridine derivatives as modulators of tnf activity
CA2871504C (en) Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease
CN110041327B (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CA3008607A1 (en) A medicament for treating influenza characterized by combining a cap-dependent endonuclease inhibitor and an anti-influenza drug
CA2931022C (en) Imidazopyridine derivatives as modulators of tnf activity
CN102329325B (zh) 吡咯并嘧啶酮类dpp-iv抑制剂
KR20170130612A (ko) 치환된 5-플루오로-1h-피라졸로피리딘의 제조 방법
RU2656209C2 (ru) Терапевтически активные производные оксазолина
CA3182595A1 (en) Immunosuppressant, and preparation method therefor and use thereof
CA2930345A1 (en) Triazolopyridazine derivatives as modulators of tnf activity
CA3056076A1 (en) A substituted-heterocyclic-c(o)o-(substituted pyridin-3-yl)compound and its use as a dual magl and faah inhibitor
CN111303147B (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CA2931587A1 (en) Tetrahydroimidazopyridine derivatives as modulators of tnf activity
AU2004208890A1 (en) Novel tricyclic azepine derivatives, method for production therof and pharmaceutical compositions comprising the same
EP1400522A1 (en) New compounds for treating impotence
CA3238521A1 (en) Heterocyclic amides and methods of using the same
HK40032909A (en) Pyridone derivative, composition thereof and application thereof as anti-influenza drug
CA3155984A1 (en) Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof
CA3185689C (en) Lpa receptor antagonists and uses thereof
EA045400B1 (ru) Пиридоновое производное, его композиция и применение в качестве противовирусного лекарственного средства
MXPA02002623A (es) Derivados de bencimidazol sustituidos, procedimiento para su preparacion y su empleo como medicamentos.
NO et al. 3rd Phase, Bangalore 560078 (IN).

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)